Sunday, January 09, 2022 2:56:30 PM
Sadly what is not understood. The saving 1 life at a time is great--while there is NEVER an approval--thousands DIE
As far as "BTD"--the FDA states --“the criteria for the breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significantly endpoint over available therapy.”
Knowing and submitting data which doesn’t achieve this, proves beyond a reasonable doubt that you and everyone on your team, don’t know the simple requirements for achieving such approval. This is at least the SECOND TIME of submitting BTD for TNBC
___________________________________________________
So are the employees/contractors of CytoDyn guilty of not knowing protocols, requirements and frankly the drugs in which they are competing against in our field??
This is either fraud or just being out of our league ,NOT knowing the basics of industry processes. Either way, “This is OUR business!” You should know everything about requirements, submissions, approval processes and competition. This is what you are hired(and VERY WELL COMPENSATED) to do!
This isn’t a drug issue or side effect issue, results issue, or even R&D issue. This is a mismanagement of filings and trials. MULTIPLE times.
I won't even discuss the BLA --NOW 4 YEARS BEHIND SCHEDULE
As far as "BTD"--the FDA states --“the criteria for the breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significantly endpoint over available therapy.”
Knowing and submitting data which doesn’t achieve this, proves beyond a reasonable doubt that you and everyone on your team, don’t know the simple requirements for achieving such approval. This is at least the SECOND TIME of submitting BTD for TNBC
___________________________________________________
So are the employees/contractors of CytoDyn guilty of not knowing protocols, requirements and frankly the drugs in which they are competing against in our field??
This is either fraud or just being out of our league ,NOT knowing the basics of industry processes. Either way, “This is OUR business!” You should know everything about requirements, submissions, approval processes and competition. This is what you are hired(and VERY WELL COMPENSATED) to do!
This isn’t a drug issue or side effect issue, results issue, or even R&D issue. This is a mismanagement of filings and trials. MULTIPLE times.
I won't even discuss the BLA --NOW 4 YEARS BEHIND SCHEDULE
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
